CDT Equity (CDT) Common Equity (2021 - 2026)
CDT Equity's (CDT) quarterly Common Equity came in at $105.5 million in Q1 2026, up 3323.73% YoY from $3.1 million in Q1 2025, and up 1570.73% on a QoQ basis from -$7.2 million in Q4 2025.
CDT Equity (CDT) Common Equity (2021 - 2026) Analysis & Trends
CDT Equity (CDT) has 6 years of Common Equity data on file, last reported at $105.5 million in Q1 2026.
- Quarterly Common Equity rose 3323.73% year-over-year to $105.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.5 million (up 3323.73% YoY) and the FY2025 annual result came in at -$7.2 million, down 5.55% from the prior year.
- Common Equity rose to $105.5 million in Q1 2026, from -$7.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $105.5 million in Q1 2026 to a low of -$14.1 million in Q2 2023.
- A 5-year average of $1.9 million and a median of -$5.5 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity slumped 168250.0% — and 2026, when it surged 3323.73%.
- Tracing CDT's Common Equity over 5 years: stood at -$10.1 million in 2022, then soared by 95.47% to -$457000.0 in 2023, then tumbled by 1386.43% to -$6.8 million in 2024, then decreased by 5.55% to -$7.2 million in 2025, then surged by 1570.73% to $105.5 million in 2026.
- The last three Common Equity figures came in at $105.5 million (Q1 2026), -$7.2 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | 103.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 103.09 Mn |
| Mar 31, 2026 | 105.45 Mn |
| Dec 31, 2025 | -7.17 Mn |
| Sep 30, 2025 | 4.28 Mn |
| Jun 30, 2025 | 3.53 Mn |
| Mar 31, 2025 | 3.08 Mn |
| Dec 31, 2024 | -6.79 Mn |
| Sep 30, 2024 | -9.12 Mn |
| Jun 30, 2024 | -5.46 Mn |
| Mar 31, 2024 | -3.10 Mn |
| Dec 31, 2023 | -457,000.00 |
| Sep 30, 2023 | 639,000.00 |
| Jun 30, 2023 | -14.14 Mn |
| Mar 31, 2023 | -12.02 Mn |
| Dec 31, 2022 | -10.09 Mn |
| Sep 30, 2022 | -6.49 Mn |
| Jun 30, 2022 | -6.14 Mn |
| Mar 31, 2022 | -3.08 Mn |
| Dec 31, 2021 | 6,000.00 |